<h4>Background</h4>Nanoparticle immunoassays for CA125 and CA15-3 glycovariants are promising tools for epithelial ovarian cancer (EOC) and borderline ovarian tumor (BOT) early detection.<h4>Method</h4>This retrospective population-based study utilized prospective (< 3 years) plasma samples from 110 cases and 440 controls. This evidence concerns the gene MUC16 and ovarian carcinoma.